Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Leflutrozole · BGS649

Small molecule · developed by Mereo BioPharma

Phase 2 Most advanced trial (none active)
MREO Developer
1 Registered trials

What is Leflutrozole?

Leflutrozole (BGS649) is an oral capsule taken weekly for up to 24 weeks. It is studied in hypogonadotropic hypogonadism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BGS649
Drug type
Small molecule
Therapy area
Endocrine
Developer
Mereo BioPharma (MREO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
RCX0IE6EJZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02908074 Phase 2 Hypogonadotropic Hypogonadism Completed MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypogonadotropic Hypogonadism

More from Mereo BioPharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.

Follow MREO, the company behind Leflutrozole

See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MREO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.